Skip to main content

DRUG INDUCED LIVER INJURY (DILI)

STEATOSIS & PHOSPHOLIPIDOSIS

IVTD’s patented human skin stem cell-derived hepatic cell model (hSKP-HPC or HepaSTARs) provides a sensitive and accurate assay for toxicity screening of novel drug candidates and the detection of drug-induced steatosis, phospholipidosis and acute liver failure, and has been tested using compounds with known toxicity, including sodium valproate and paracetamol. The hSKP-HPC model compares favourably with human hepatocytes, HepG2 and HepaRG™ cells in assessing hepatotoxicty. 

 

PUBLICATIONS

SEEKING COLLABORATIONS/CANDIDATES

led by Tamara Vanhaecke

  • miniaturisation of DILI prediction in hSKP-HPC model towards high-throughput drug screening

CHOLESTASIS

Mechanistic study of cholestatic liver injury using adverse outcome pathways as the basis for improved in vitro detection of liver toxicity. 

 

Publications

Current projects

led by Mathieu Vinken 

  • Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury

  • The role of connexins, pannexins, and their channels, in cholestasis
  • Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury